Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab : insights from the phase II PRIMMO trial

Source
Gynecologic oncology - ISSN 0090-8258-191 (2024) p. 275-286
Author(s)
    Emiel A. De Jaeghere, Hannelore Hamerlinck, Sandra Tuyaerts, Lien Lippens, An M.T. Van Nuffel, Regina Baiden-Amissah, Peter Vuylsteke, Stephanie Henry, Xuan Bich Trinh, Peter André Van Dam, Sandrine Aspeslagh, Alex De Caluwe, Eline Naert, Diether Lambrechts, An Hendrix, Olivier De Wever, Koen Van de Vijver, Frederic Amant, Katrien Vandecasteel, Bruno Verhasselt, Hannelore G. Denys

An open-label, single-arm, prospective, multi-center, tandem two-stage designed phase II study to evaluate the efficacy of fulvestrant in women with recurrent/metastatic estrogen receptor-positive gynecological malignancies (FUCHSia study)

Source
International journal of gynecological cancer - ISSN 1048-891X-34:8 (2024) p. 1217-1224
Author(s)
    Rita Trozzi, Sandra Tuyaerts, Daniela Annibali, Alejandro Herreros Pomares, Lotte Boog, Peter André Van Dam, Karin Leunen, Christophe Deroose, Hans Trum, Frédéric Amant

XIAP overexpressing inflammatory breast cancer patients have high infiltration of immunosuppressive subsets and increased TNFR1 signaling targetable with Birinapant

Source
Translational oncology - ISSN 1936-5233-43 (2024) p. 1-13
Author(s)

Quality of surgery and treatment and its association with hospital volume : a population-based study in more than 5000 Belgian ovarian cancer patients

Source
European journal of surgical oncology - ISSN 0748-7983-50:3 (2024) p. 1-8
Author(s)
    Jolyce Bourgeois, Hanna M. Peacock, Isabelle Savoye, Cindy De Gendt, Roos Leroy, Geert Silversmit, Sabine Stordeur, Philippe de Sutter, Frederic Goffin, Mathieu Luyckx, Guy Orye, Peter André Van Dam, Toon Van Gorp, Leen Verleye